NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









EnteroBiotix

EnteroBiotix

Private
GlasgowHealthcare & Life Scienceshttps://www.enterobiotix.com/

Last Round

Seed Round

Apr 9, 2026

Total Funding Raised

$59.09M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

EnteroBiotix is a biotechnology company that develops microbiome-modulating drugs aimed at restoring health and preventing bacterial infections through tailored high-diversity microbial therapeutics for patients with serious unmet medical needs.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Clinical Trials, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

microbiome therapeuticsgut microbiomemicrobiome dysbiosisfecal microbiota transplantFMTbiotechnologybiotechclinical-stage biotechdrug discoveryGMP manufacturingprecision medicineclinical trialslive biotherapeutic productsLBPsgut health

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

EnteroBiotix Comparables

Compare EnteroBiotix with similar companies based on industry and business-model similarity.

EnteroBiotix comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Microbiotica
85%
BiomeBank
83%
Human Biome S.A.
82%

EnteroBiotix Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Seed RoundApr 9, 2026
Series BApr 4, 2024
Series ASep 7, 2021
SeedMay 29, 2019
SeedJun 21, 2017
Grant
Jun 21, 2017

Key People

Founding team and executive leadership

James McIlroy

Chief Executive Officer, Founder

Founding Team

James Barnes

Chief Operating Officer

Executive Team

EnteroBiotix Investors

Notable investors and investment history

EnteroBiotix investors
InvestorRounds
University of AberdeenSeed
Gabriel Investments LtdSeed
Kineticos VenturesSeries A, Series B
Equity GapSeries B, Seed
Scottish EDGEGrant
Scottish National Investment BankSeed, Series A, Series B, Seed Round
Barwell PlcSeed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 29, 2026

    Lead candidate EBX-102-02 advances to Phase 2b for IBS-C treatment.

  • Apr 9, 2026

    Raised $5.3M in a Seed Round.

EnteroBiotix Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

EnteroBiotix Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about EnteroBiotix's valuation, stock price, and market status.

Firmographic Details

HeadquartersGlasgow
Employee Range45
Year Founded2017
Last FundingApr 9, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.